Proteome Sciences plc Notice of Results

The Directors look forward to updating shareholders on the Company’s performance, and on the outlook for 2018, at the time they announce their 2017 full year results which are scheduled for release on 24 April 2018. 

Annual General Meeting

The Annual General Meeting will take place in London during the last week of May 2018 and further details will be provided in due course.

 

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant®) and for the discovery, validation and assay development of protein biomarkers (TMTcalibrator). The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Proteome Sciences Plc

    More articles like this

    Proteome Sciences Plc

    Proteome Sciences plc Board Appointment

    Proteome Sciences plc (LON:PRM) has today announced that Mr Richard Dennis has today been appointed to the Board of Directors.  As communicated on 3 April 2017, when he joined the Company as its first Chief Commercial

    Proteome Sciences Plc

    Proteome Sciences plc License Agreement Extension

    Electrophoretics Ltd, a wholly owned subsidiary of Proteome Sciences plc (LON:PRM), is pleased to announce that it has signed an amendment to the exclusive License and Distribution Agreement with Pierce Biotechnology Inc., a part of Thermo Fisher

    Proteome Sciences Plc

    Proteome Sciences plc accreditation for clinical stage contracts

    Proteome Sciences plc has this morning announced the receipt of Good Clinical Laboratory Practice (GCLP) accreditation which will now enable it to compete effectively for clinical stage contracts commanding routinely larger budgets; the benefits of this

    Proteome Sciences Plc

    Proteome Sciences sales and royalties have increased 40%

    Proteome Sciences LON:PRM has given DirectorsTalk its unaudited interim results for the six months ended 30 June 2017. Financial highlights: — Total revenues increased 21% to GBP1.36m (2016: GBP1.12m) — TMT(R) reagent sales and royalties increased